Clinical Trial Update: Phase I/II Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating ONC-PluReceptor NK cells in combination with epcoritamab and tafasitamab for patients with recurrent or refractory B-ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• EPKINLY (EPCORITAMAB-BYSP)
• Monjuvi (tafasitamab)
• ONC-PluReceptor NK Cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING